Enfusion Announces Fourth Quarter and Full Year 2024 Results
Enfusion (NYSE: ENFN) reported strong Q4 and full-year 2024 financial results, showcasing steady growth across key metrics. Q4 revenue reached $52.9 million, up 13.9% year-over-year, with a gross profit of $36.5 million and 69.0% margin. The company achieved a net income of $0.2 million and Adjusted EBITDA of $12.3 million, up 25.3% from the previous year.
Full-year 2024 performance showed total revenue of $201.6 million, representing a 15.5% increase from 2023's $174.5 million. The company maintained strong profitability with a 67.8% gross profit margin and 21.2% Adjusted EBITDA margin. Annual Recurring Revenue reached $210.4 million, up 13.6% year-over-year, while the Net Dollar Retention Rate improved to 103.0%.
Notably, Enfusion added 41 new clients in Q4, bringing the total client count to 916. The company has entered into a definitive agreement to be acquired by Clearwater Analytics, with the transaction expected to close in Q2 2025, subject to shareholder and regulatory approvals.
Enfusion (NYSE: ENFN) ha riportato risultati finanziari solidi per il quarto trimestre e per l'intero anno 2024, mostrando una crescita costante in tutti i principali indicatori. Le entrate del quarto trimestre hanno raggiunto 52,9 milioni di dollari, con un aumento del 13,9% rispetto all'anno precedente, e un utile lordo di 36,5 milioni di dollari con un margine del 69,0%. L'azienda ha registrato un reddito netto di 0,2 milioni di dollari e un EBITDA rettificato di 12,3 milioni di dollari, in aumento del 25,3% rispetto all'anno precedente.
Le performance dell'intero anno 2024 hanno mostrato entrate totali di 201,6 milioni di dollari, rappresentando un aumento del 15,5% rispetto ai 174,5 milioni di dollari del 2023. L'azienda ha mantenuto una forte redditività con un margine di utile lordo del 67,8% e un margine di EBITDA rettificato del 21,2%. Le entrate ricorrenti annuali hanno raggiunto 210,4 milioni di dollari, con un incremento del 13,6% rispetto all'anno precedente, mentre il tasso di retention netto è migliorato al 103,0%.
In particolare, Enfusion ha aggiunto 41 nuovi clienti nel quarto trimestre, portando il totale a 916. L'azienda ha stipulato un accordo definitivo per essere acquisita da Clearwater Analytics, con la transazione prevista per chiudere nel secondo trimestre del 2025, soggetta all'approvazione degli azionisti e delle autorità di regolamentazione.
Enfusion (NYSE: ENFN) reportó resultados financieros sólidos para el cuarto trimestre y el año completo 2024, mostrando un crecimiento constante en métricas clave. Los ingresos del cuarto trimestre alcanzaron 52.9 millones de dólares, un aumento del 13.9% interanual, con una ganancia bruta de 36.5 millones de dólares y un margen del 69.0%. La empresa logró un ingreso neto de 0.2 millones de dólares y un EBITDA ajustado de 12.3 millones de dólares, un incremento del 25.3% respecto al año anterior.
El desempeño del año completo 2024 mostró ingresos totales de 201.6 millones de dólares, representando un aumento del 15.5% desde los 174.5 millones de dólares de 2023. La empresa mantuvo una fuerte rentabilidad con un margen de ganancia bruta del 67.8% y un margen de EBITDA ajustado del 21.2%. Los ingresos recurrentes anuales alcanzaron 210.4 millones de dólares, un aumento del 13.6% interanual, mientras que la tasa de retención neta mejoró al 103.0%.
Notablemente, Enfusion agregó 41 nuevos clientes en el cuarto trimestre, llevando el total a 916. La empresa ha firmado un acuerdo definitivo para ser adquirida por Clearwater Analytics, con la transacción prevista para cerrarse en el segundo trimestre de 2025, sujeta a la aprobación de los accionistas y de las autoridades regulatorias.
Enfusion (NYSE: ENFN)은 2024년 4분기 및 연간 재무 결과를 발표하며 주요 지표에서 안정적인 성장을 보여주었습니다. 4분기 수익은 5,290만 달러에 달하며, 전년 대비 13.9% 증가했으며, 총 이익은 3,650만 달러, 마진은 69.0%입니다. 회사는 20만 달러의 순이익과 1,230만 달러의 조정 EBITDA를 달성했으며, 이는 전년 대비 25.3% 증가한 수치입니다.
2024년 전체 성과는 총 수익 2억 1,600만 달러를 기록하며, 2023년의 1억 7,450만 달러에서 15.5% 증가했습니다. 회사는 67.8%의 총 이익 마진과 21.2%의 조정 EBITDA 마진을 유지하며 강력한 수익성을 유지했습니다. 연간 반복 수익은 2억 1,040만 달러에 달하며, 전년 대비 13.6% 증가했으며, 순 달러 유지율은 103.0%로 개선되었습니다.
특히 Enfusion은 4분기에 41명의 신규 고객을 추가하여 총 고객 수를 916명으로 늘렸습니다. 회사는 Clearwater Analytics에 인수되기 위한 확정 계약을 체결했으며, 이 거래는 2025년 2분기에 종료될 예정이며, 주주 및 규제 당국의 승인을 받을 것입니다.
Enfusion (NYSE: ENFN) a annoncé des résultats financiers solides pour le quatrième trimestre et l'année entière 2024, montrant une croissance constante dans les principaux indicateurs. Les revenus du quatrième trimestre ont atteint 52,9 millions de dollars, en hausse de 13,9 % par rapport à l'année précédente, avec un bénéfice brut de 36,5 millions de dollars et une marge de 69,0 %. L'entreprise a réalisé un revenu net de 0,2 million de dollars et un EBITDA ajusté de 12,3 millions de dollars, en hausse de 25,3 % par rapport à l'année précédente.
La performance de l'année 2024 a montré un revenu total de 201,6 millions de dollars, représentant une augmentation de 15,5 % par rapport aux 174,5 millions de dollars de 2023. L'entreprise a maintenu une forte rentabilité avec une marge de bénéfice brut de 67,8 % et une marge d'EBITDA ajustée de 21,2 %. Le revenu récurrent annuel a atteint 210,4 millions de dollars, en hausse de 13,6 % par rapport à l'année précédente, tandis que le taux de rétention net a amélioré à 103,0 %.
Notamment, Enfusion a ajouté 41 nouveaux clients au quatrième trimestre, portant le total à 916. L'entreprise a conclu un accord définitif pour être acquise par Clearwater Analytics, la transaction devant être finalisée au deuxième trimestre de 2025, sous réserve de l'approbation des actionnaires et des régulateurs.
Enfusion (NYSE: ENFN) hat starke Finanzzahlen für das vierte Quartal und das gesamte Jahr 2024 veröffentlicht und dabei ein stetiges Wachstum in den wichtigsten Kennzahlen gezeigt. Der Umsatz im vierten Quartal erreichte 52,9 Millionen Dollar, was einem Anstieg von 13,9% im Jahresvergleich entspricht, mit einem Bruttogewinn von 36,5 Millionen Dollar und einer Marge von 69,0%. Das Unternehmen erzielte einen Nettogewinn von 0,2 Millionen Dollar und ein bereinigtes EBITDA von 12,3 Millionen Dollar, was einem Anstieg von 25,3% im Vergleich zum Vorjahr entspricht.
Die Leistung im gesamten Jahr 2024 zeigte einen Gesamtumsatz von 201,6 Millionen Dollar, was einem Anstieg von 15,5% gegenüber 174,5 Millionen Dollar im Jahr 2023 entspricht. Das Unternehmen hielt eine starke Rentabilität mit einer Bruttogewinnmarge von 67,8% und einer bereinigten EBITDA-Marge von 21,2%. Die wiederkehrenden Jahresumsätze erreichten 210,4 Millionen Dollar, was einem Anstieg von 13,6% im Jahresvergleich entspricht, während die Netto-Dollarrückhaltungsrate auf 103,0% verbessert wurde.
Bemerkenswert ist, dass Enfusion im vierten Quartal 41 neue Kunden hinzugewonnen hat, was die Gesamtzahl auf 916 erhöht. Das Unternehmen hat eine endgültige Vereinbarung zur Übernahme durch Clearwater Analytics getroffen, wobei die Transaktion voraussichtlich im zweiten Quartal 2025 abgeschlossen wird, vorbehaltlich der Genehmigung durch die Aktionäre und der Aufsichtsbehörden.
- Revenue up 15.5% YoY to $201.6M
- Adjusted EBITDA margin improved to 21.2% from 18.1%
- ARR grew 13.6% to $210.4M
- Added 41 new clients in Q4
- Net Dollar Retention Rate improved to 103.0%
- Gross Profit Margin increased to 67.8%
- Net Income Margin declined to 1.9% from 5.3%
- Q4 Net Income of only $0.2M with 0.3% margin
Insights
Enfusion's Q4 2024 results demonstrate solid growth momentum with 13.9% year-over-year revenue increase to
Enfusion's SaaS business model continues to deliver reliable recurring revenue, with ARR reaching
The pending acquisition by Clearwater Analytics represents a significant strategic development, expected to close in Q2 2025. This consolidation aligns with the broader trend of fintech integration in investment management software, potentially creating a more comprehensive solution set for the combined entity's clients. While net income margin decreased year-over-year from
The announced merger with Clearwater Analytics represents a strategic consolidation within the investment management software sector that should strengthen both companies' competitive positions. Clearwater's acquisition of Enfusion combines complementary platforms – Clearwater's investment accounting and reporting capabilities with Enfusion's front-to-back office investment management system – creating a more comprehensive solution for institutional investors.
Enfusion's consistent client growth trajectory – adding 41 new clients in Q4 alone – validates its product-market fit in the investment management software space. The
The company's
This consolidation follows the broader enterprise software industry pattern where platform expansion through M&A creates more comprehensive solutions for clients. For Enfusion shareholders, this acquisition likely represents the culmination of the company's growth strategy, providing an exit opportunity while potentially delivering a more complete solution to existing clients as part of a larger organization with greater resources.
Fourth Quarter 2024 Financial Highlights:
-
Total revenue was
$52.9 million 13.9% compared to the same period in the prior year. -
Gross Profit was
$36.5 million 69.0% . -
Adjusted Gross Profit was
$36.9 million 69.6% . -
Net Income was
$0.2 million 0.3% . -
Adjusted EBITDA was
$12.3 million 25.3% compared to the same period in the prior year. -
Operating Cash Flow was
$9.7 million -
Adjusted Free Cash Flow was
$7.7 million 62.7% . -
Annual Recurring Revenue (ARR) was
$210.4 million 13.6% from December 2023. -
Net Dollar Retention Rate (NDR) was
103.0% , compared to102.1% from December 2023.
Fourth Quarter 2024 Business Highlights:
- Total client count of 916 as of December 31, 2024.
- 41 new clients were added in the fourth quarter.
Full Year 2024 Financial Highlights:
-
Total revenue was
$201.6 million 15.5% compared to$174.5 million -
Gross Profit Margin was
67.8% , compared to67.0% in the prior year. -
Adjusted Gross Profit Margin was
68.7% , compared to67.6% in the prior year. -
Net Income Margin was
1.9% , compared to5.3% in the prior year. -
Adjusted EBITDA Margin was
21.2% , compared to18.1% in the prior year.
Transaction with Clearwater Analytics
On January 13, 2025, Enfusion announced its entry into a definitive agreement (the “Merger Agreement”) to be acquired by Clearwater Analytics. Details and information about the terms and conditions of the Merger Agreement and the transactions contemplated by the Merger Agreement are available in the Current Report on Form 8-K filed with the SEC on January 13, 2025. The transaction is anticipated to close in the second quarter of 2025, subject to approval by Enfusion shareholders, the receipt of required regulatory approvals, and customary closing conditions.
In light of the announced transaction, Enfusion will not be hosting an earnings conference call, releasing a Shareholder Letter, or providing financial guidance for fiscal 2025.
About Enfusion
Enfusion's investment management software-as-a-service platform removes traditional information boundaries, uniting front-, middle- and back-office teams on one system. Through its software, analytics, and middle/back-office managed services, Enfusion creates enterprise-wide cultures of real-time, data-driven intelligence and collaboration boosting agility and powering growth. Enfusion partners with over 900 investment managers from 9 global offices spanning four continents. For more information, please visit www.enfusion.com.
Definitions:
Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with GAAP, this presentation and the accompanying tables include Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Free Cash Flow, Adjusted Gross Profit, Adjusted Gross Margin, Adjusted Net Income and FCF Conversion, which are non-GAAP financial measures. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP.
Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Free Cash Flow, Adjusted Gross Profit, Adjusted Gross Margin, Adjusted Net Income and FCF Conversion are supplemental measures of our operating performance and liquidity that are neither required by, nor presented in accordance with,
These measures are presented because they are the primary measures used by management to evaluate our financial performance and liquidity, and for forecasting purposes. This non-GAAP financial information is useful to investors because it eliminates certain items that affect period-over-period comparability and provides consistency with past financial performance or liquidity and additional information about underlying results and trends by excluding certain items that may not be indicative of our business, results of operations or outlook. Additionally, we believe that these and similar measures are often used by securities analysts, investors and other interested parties as a means of evaluating a company’s operating performance.
Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Free Cash Flow, Adjusted Gross Profit, Adjusted Gross Margin, Adjusted Net Income and FCF Conversion are non-GAAP financial measures, are not measurements of our financial performance or liquidity under
Adjusted EBITDA and Adjusted EBITDA Margin
Adjusted EBITDA represents earnings before interest, taxes, depreciation and amortization, adjusted to exclude stock-based compensation expense, the effect of foreign currency fluctuations, and certain non-recurring items. Adjusted EBITDA Margin represents Adjusted EBITDA divided by total net revenues.
Adjusted Free Cash Flow and FCF Conversion
Adjusted Free Cash Flow represents net cash provided from operating activities, less purchases of property and equipment, capitalized software development costs, and other nonrecurring items. However, given our non-discretionary expenditures, Adjusted Free Cash Flow does not represent residual cash flow available for discretionary expenditures. FCF Conversion represents Adjusted Free Cash Flow divided by Adjusted EBITDA.
Adjusted Net Income and Adjusted Diluted EPS
Adjusted Net Income represents net income adjusted to exclude stock-based compensation expense, the effect of foreign currency fluctuations, certain non-recurring items, and the tax effect of such adjustments. Adjusted Diluted EPS represents Adjusted Net Income divided by fully diluted weighted average shares outstanding.
Adjusted Gross Profit and Adjusted Gross Margin
Adjusted Gross Profit represents gross profit, excluding the impact of stock-based compensation and other non-recurring items. Adjusted Gross Margin represents Adjusted Gross Profit divided by total net revenues.
Key Metrics:
In connection with the management of our business, we identify, measure and assess a variety of key metrics. The key metrics we use in managing our business are set forth below.
Annual Recurring Revenue
We calculate Annual Recurring Revenue, or ARR, by annualizing platform subscriptions and managed services revenues recognized in the last month of the measurement period. We believe ARR provides important information about our future revenue potential, our ability to acquire new clients and our ability to maintain and expand our relationship with existing clients. ARR is included in a set of metrics we calculate monthly to review with management as well as periodically with our board of directors.
Average Contract Value
We calculate Average Contract Value, or ACV, by dividing ARR by the number of clients that are billed at the end of the measurement period. We believe ACV is an important metric because it provides important information about the growth of our clients' accounts. Investors should not place undue reliance on ARR or Net Dollar Retention Rate or Average Contract Value as an indicator of future or expected results. Our presentation of these metrics may differ from similarly titled metrics presented by other companies and therefore comparability may be limited.
Net Dollar Retention Rate
We calculate Net Dollar Retention Rate as of a period end by starting with the ARR for all clients as of twelve months prior to such period end, or Prior Period ARR. We then calculate the ARR from those same clients as of the current period end, or Current Period ARR. Current Period ARR includes expansion within existing clients inclusive of contraction and voluntary attrition and involuntary cancellations. We define involuntary cancellations as accounts that were cancelled due to the client no longer being in business. Post 4Q23, we no longer provide the Net Dollar Retention Rate calculation excluding involuntary cancellation calculations.
Our Net Dollar Retention Rate is equal to the Current Period ARR divided by the Prior Period ARR. We believe Net Dollar Retention Rate is an important metric because, in addition to providing a measure of retention, it indicates our ability to grow revenues within existing client accounts.
OCF Margin
Operating Cash Flow Margin represents net cash provided from operating activities divided by total net revenues. We believe OCF Margin is an important metric because it indicates our ability to convert sales into cash.
Forward-Looking Statements
This communication contains forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. All statements other than statements of historical facts contained in this communication, including statements regarding the proposed transaction and its expected timing, completion and effects, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipates,”, “believes,” “estimates,” “expects,” “plans,” “potential,” “will,” or the negative of these words or other similar terms or expressions that concern the Company’s expectations, strategy, plans or intentions.
Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors. Important factors that could cause actual outcomes or results to differ materially from the forward-looking statements include, but are not limited to, (a) the ability of the parties to consummate the proposed transaction in a timely manner or at all; (b) the satisfaction (or waiver) of closing conditions to the consummation of the proposed transaction; (c) potential delays in consummating the proposed transaction; (d) the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the proposed transaction that could delay the consummation of the proposed transaction or cause the parties to abandon the proposed transaction; (e) the possibility that the Company’s stockholders may not approve the proposed transaction; (f) the ability of the Company to timely and successfully achieve the anticipated benefits of the proposed transaction; (g) the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement; (h) the Company’s ability to implement its business strategy; (i) significant transaction costs associated with the proposed transaction; (j) the possibility that the proposed transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (k) potential litigation relating to the proposed transaction; (l) the risk that disruptions from the proposed transaction will harm the Company’s business, including current plans and operations; (m) the ability of the Company to retain and hire key personnel; (n) potential adverse reactions or changes to business relationships of the Company resulting from the announcement or completion of the proposed transaction; (o) legislative, regulatory and economic developments affecting the Company’s business; (p) general economic and market developments and conditions; (q) the legal, regulatory and tax regimes under which the Company operates; (r) potential business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction that could affect the Company’s financial performance; (s) the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of the Company’s Class A common stock; (t) restrictions during the pendency of the proposed transaction that may impact the Company’s ability to pursue certain business opportunities or strategic transactions;; and (u) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as the Company’s response to any of the aforementioned factors. These risks, as well as other risks related to the proposed transaction, will be included in the registration statement on Form S-4 and joint proxy/statement prospectus that will be filed with the SEC in connection with the proposed transaction.
For information regarding other factors that could cause the Company’s results to vary from expectations, please see the “Risk Factors” section of the Company’s respective periodic report filings with the SEC, including but not limited to the Company’s most recent Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K as well as other documents that may be filed by the Company from time to time with the SEC. While the list of factors presented here is, and the list of factors to be presented in the registration statement on Form S-4 and joint proxy/statement prospectus are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. The statements in this communication are made only as of the date hereof. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Source: Enfusion, Inc.
Source Code: ENFN-IR
ENFN-CORP
ENFUSION, INC.
CONSOLIDATED BALANCE SHEETS
(dollars and shares in thousands, except per share amounts)
(Unaudited)
| December 31, | ||||||||
2024 |
|
|
|
2023 |
|
|||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 54,480 |
|
$ | 35,604 |
|
||
| Accounts receivable, net | 31,988 |
|
28,069 |
|
||||
| Prepaid expenses | 5,342 |
|
5,009 |
|
||||
| Other current assets | 1,711 |
|
1,170 |
|
||||
| Total current assets | 93,521 |
|
69,852 |
|
||||
| Notes receivable, net | 3,000 |
|
— |
|
||||
| Property, equipment, and software, net | 20,963 |
|
18,314 |
|
||||
| Right-of-use-assets, net | 18,062 |
|
14,304 |
|
||||
| Other assets | 7,715 |
|
6,502 |
|
||||
| Total assets | $ | 143,261 |
|
$ | 108,972 |
|
||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 867 |
|
$ | 2,212 |
|
||
| Accrued expenses and other current liabilities | 20,393 |
|
13,841 |
|
||||
| Current portion of lease liabilities | 6,076 |
|
4,256 |
|
||||
| Total current liabilities | 27,336 |
|
20,309 |
|
||||
| Lease liabilities, net of current portion | 14,236 |
|
11,181 |
|
||||
| Other non-current liabilities | 2,150 |
|
— |
|
||||
| Total liabilities | 43,722 |
|
31,490 |
|
||||
| Commitment and contingencies (Note 9) | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, |
— |
|
— |
|
||||
| Class A common stock, |
95 |
|
88 |
|
||||
| Class B common stock, |
34 |
|
39 |
|
||||
| Additional paid-in capital | 243,935 |
|
226,877 |
|
||||
| Accumulated deficit | (170,109 |
) |
(172,932 |
) |
||||
| Accumulated other comprehensive loss | (734 |
) |
(406 |
) |
||||
| Total stockholders’ equity attributable to Enfusion, Inc. | 73,221 |
|
53,666 |
|
||||
| Non-controlling interests | 26,318 |
|
23,816 |
|
||||
| Total stockholders’ equity | 99,539 |
|
77,482 |
|
||||
| Total liabilities and stockholders’ equity | $ | 143,261 |
|
$ | 108,972 |
|
||
ENFUSION, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(dollars and shares in thousands, except per share amounts)
(Unaudited)
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||
2024 |
|
2023 |
|
|
2024 |
|
|
2023 |
|
||||||
| REVENUES: | |||||||||||||||
| Platform subscriptions | $ | 49,252 |
43,054 |
|
$ | 187,521 |
|
$ | 161,519 |
|
|||||
| Managed services | 3,211 |
3,056 |
|
12,689 |
|
11,773 |
|
||||||||
| Other | 475 |
376 |
|
1,401 |
|
1,243 |
|
||||||||
| Total revenues | 52,938 |
46,486 |
|
201,611 |
|
174,535 |
|
||||||||
| COST OF REVENUES: | |||||||||||||||
| Platform subscriptions | 14,555 |
13,759 |
|
57,727 |
|
50,702 |
|
||||||||
| Managed services | 1,600 |
1,725 |
|
6,564 |
|
6,514 |
|
||||||||
| Other | 243 |
140 |
|
583 |
|
425 |
|
||||||||
| Total cost of revenues | 16,398 |
15,624 |
|
64,874 |
|
57,641 |
|
||||||||
| Gross profit | 36,540 |
30,862 |
|
136,737 |
|
116,894 |
|
||||||||
| OPERATING EXPENSES: | |||||||||||||||
| General and administrative | 21,148 |
17,115 |
|
78,826 |
|
64,635 |
|
||||||||
| Sales and marketing | 6,570 |
5,552 |
|
25,029 |
|
20,418 |
|
||||||||
| Technology and development | 7,238 |
6,061 |
|
26,727 |
|
19,893 |
|
||||||||
| Total operating expenses | 34,956 |
28,728 |
|
130,582 |
|
104,946 |
|
||||||||
| Income from operations | 1,584 |
2,134 |
|
6,155 |
|
11,948 |
|
||||||||
| NON-OPERATING INCOME (EXPENSE): | |||||||||||||||
| Payment to related party | — |
— |
|
— |
|
(1,501 |
) |
||||||||
| Interest income, net | 533 |
356 |
|
1,693 |
|
1,641 |
|
||||||||
| Other income (expense), net | 341 |
(310 |
) |
(459 |
) |
(604 |
) |
||||||||
| Total non-operating income (expense) | 874 |
46 |
|
1,234 |
|
(464 |
) |
||||||||
| Income before income taxes | 2,458 |
2,180 |
|
7,389 |
|
11,484 |
|
||||||||
| Income taxes | 2,286 |
1,280 |
|
3,474 |
|
2,231 |
|
||||||||
| Net income | 172 |
900 |
|
3,915 |
|
9,253 |
|
||||||||
| Net income attributable to non-controlling interests | 51 |
277 |
|
1,092 |
|
3,228 |
|
||||||||
| Net income attributable to Enfusion, Inc. | $ | 121 |
$ | 623 |
|
$ | 2,823 |
|
$ | 6,025 |
|
||||
| Net income per Class A common shares attributable to Enfusion, Inc.: | |||||||||||||||
| Basic | $ | 0.00 |
$ | 0.01 |
|
$ | 0.03 |
|
$ | 0.07 |
|
||||
| Diluted | $ | 0.00 |
$ | 0.01 |
|
$ | 0.03 |
|
$ | 0.07 |
|
||||
| Weighted-average number of Class A common shares outstanding: | |||||||||||||||
| Basic | 94,262 |
88,280 |
|
92,045 |
|
88,202 |
|
||||||||
| Diluted | 129,558 |
127,765 |
|
129,550 |
|
129,429 |
|
||||||||
ENFUSION, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(dollars in thousands)
(Unaudited)
| December 31, | ||||||||
2024 |
|
|
2023 |
|
||||
| Cash flows from operating activities: | ||||||||
| Net income | $ | 3,915 |
|
$ | 9,253 |
|
||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Non-cash lease expense | 7,383 |
|
6,882 |
|
||||
| Depreciation and amortization | 11,754 |
|
9,987 |
|
||||
| Provision for credit losses | 229 |
|
1,319 |
|
||||
| Amortization of debt-related costs | 234 |
|
92 |
|
||||
| Loss on extinguishment of debt | — |
|
78 |
|
||||
| Stock-based compensation expense | 19,033 |
|
7,458 |
|
||||
| Change in operating assets and liabilities: | ||||||||
| Accounts receivable | (4,147 |
) |
(3,679 |
) |
||||
| Prepaid expenses and other assets | (4,788 |
) |
(1,749 |
) |
||||
| Accounts payable | (1,185 |
) |
365 |
|
||||
| Accrued compensation | 3,675 |
|
(729 |
) |
||||
| Accrued expenses and other liabilities | 2,675 |
|
2,359 |
|
||||
| Lease liabilities | (6,264 |
) |
(6,002 |
) |
||||
| Other non-current liabilities | 2,168 |
|
— |
|
||||
| Net cash provided by operating activities | 34,682 |
|
25,634 |
|
||||
| Cash flows from investing activities: | ||||||||
| Purchases of property and equipment | (3,635 |
) |
(4,453 |
) |
||||
| Capitalization of software development costs | (7,257 |
) |
(5,218 |
) |
||||
| Purchase of convertible promissory note | (3,000 |
) |
— |
|
||||
| Net cash used in investing activities | (13,892 |
) |
(9,671 |
) |
||||
| Cash flows from financing activities: | ||||||||
| Distributions to non-controlling interests | (136 |
) |
— |
|
||||
| Settlement of tax receivable acquired in reorganization transactions | — |
|
1,501 |
|
||||
| Issuance of Class A common stock, net of issuance costs | — |
|
17,322 |
|
||||
| Payment of withholding taxes on stock-based compensation | (1,267 |
) |
(60,447 |
) |
||||
| Payment of debt issuance and debt facility costs | — |
|
(1,151 |
) |
||||
| Other financing activities | — |
|
(308 |
) |
||||
| Net cash used in financing activities | (1,403 |
) |
(43,083 |
) |
||||
| Effect of exchange rate changes on cash and cash equivalents | (511 |
) |
179 |
|
||||
| Net increase (decrease) in cash and cash equivalents | 18,876 |
|
(26,941 |
) |
||||
| Cash and cash equivalents, beginning of period | 35,604 |
|
62,545 |
|
||||
| Cash and cash equivalents, end of period | $ | 54,480 |
|
$ | 35,604 |
|
||
Reconciliations To Non-GAAP Financial Measures
The following table reconciles Gross Profit to Adjusted Gross Profit:
| Three Months Ended | |||||||||||||||
| ($ in thousands, unaudited) | December 31, 2023 |
|
March 31, 2024 |
|
June 30, 2024 |
|
September 30, 2024 |
|
December 31, 2024 |
||||||
| GAAP Gross Profit | $ | 30,862 |
|
31,878 |
|
33,493 |
|
34,826 |
|
36,540 |
|
||||
| Add back stock-based compensation expense | 230 |
|
717 |
|
392 |
|
358 |
|
314 |
|
|||||
| Adjusted Gross Profit | $ | 31,092 |
|
32,595 |
|
33,885 |
|
35,184 |
|
36,854 |
|
||||
| Adjusted Gross Margin | 66.9 |
% |
67.8 |
% |
68.5 |
% |
68.8 |
% |
69.6 |
% |
|||||
The following table reconciles Net Income to Adjusted EBITDA:
| Three Months Ended | |||||||||||||||
| ($ in thousands, unaudited) | December 31, 2023 |
|
March 31, 2024 |
|
June 30, 2024 |
|
September 30, 2024 |
|
December 31, 2024 |
||||||
| Net income (loss) | $ | 900 |
|
(761 |
) |
2,547 |
|
1,957 |
|
172 |
|
||||
| Interest income | (356 |
) |
(317 |
) |
(356 |
) |
(487 |
) |
(533 |
) |
|||||
| Income tax expense (benefit) | 1,280 |
|
(117 |
) |
401 |
|
904 |
|
2,286 |
|
|||||
| Depreciation and amortization | 3,512 |
|
2,674 |
|
2,872 |
|
2,967 |
|
3,252 |
|
|||||
| EBITDA | $ | 5,336 |
|
1,479 |
|
5,464 |
|
5,341 |
|
5,177 |
|
||||
| Adjustments: | |||||||||||||||
| Stock-based compensation expense | 3,404 |
|
7,001 |
|
4,101 |
|
4,198 |
|
3,733 |
|
|||||
| Tax payment on stock-based compensation | 60 |
|
429 |
|
101 |
|
25 |
|
91 |
|
|||||
| Effects of foreign currency | 308 |
|
82 |
|
111 |
|
607 |
|
(445 |
) |
|||||
| Other non-recurring items1,2,3,4,5 | 678 |
|
188 |
|
354 |
|
977 |
|
3,712 |
|
|||||
| Adjusted EBITDA | $ | 9,787 |
|
9,179 |
|
10,131 |
|
11,148 |
|
12,268 |
|
||||
| Adjusted EBITDA Margin | 21.1 |
% |
19.1 |
% |
20.5 |
% |
21.8 |
% |
23.2 |
% |
|||||
| 1 For the three months ended December 31, 2023, primarily includes the write-off of capitalized software and licenses related to a project which was abandoned in the fourth quarter of 2023 after management's decision to pursue an alternative path. 2 For the three months ended March 31, 2024, includes the sign-on bonus for the newly-appointed Chief Operating Officer. 3 For the three months ended June 30, 2024, includes temporary double occupancy related to office relocations. 4 For the three months ended September 30, 2024, includes professional fees incurred in conjunction with the pending Clearwater merger. 5 For the three months ended December 31, 2024, includes corporate restructuring and professional fees incurred in conjunction with the pending Clearwater merger. |
The following table reconciles Operating Cash Flow to Adjusted Free Cash Flow:
| Three Months Ended | |||||||||||||||
| ($ in thousands, unaudited) | December 31, 2023 |
|
March 31, 2024 |
|
June 30, 2024 |
|
September 30, 2024 |
|
December 31, 2024 |
||||||
| Net cash provided by operating activities | $ | 6,586 |
|
1,533 |
|
7,314 |
|
16,162 |
|
9,673 |
|
||||
| Purchases of property and equipment | (1,205 |
) |
(635 |
) |
(1,005 |
) |
(1,104 |
) |
(891 |
) |
|||||
| Capitalization of software development costs | (1,090 |
) |
(2,113 |
) |
(1,701 |
) |
(1,671 |
) |
(1,772 |
) |
|||||
| Other non-recurring items1 | — |
|
— |
|
— |
|
353 |
|
685 |
|
|||||
| Adjusted Free Cash Flow | $ | 4,291 |
|
(1,215 |
) |
4,608 |
|
13,740 |
|
7,695 |
|
||||
| 1 For the three months ended September 30, 2024 and December 31, 2024, includes professional fees incurred in conjunction with the pending Clearwater merger. |
The Company’s stock-based compensation expense was recognized in the following captions within the Consolidated Statements of Operations:
| Three Months Ended December 31, | |||||
| ($ in thousands, unaudited) | 2024 |
|
|
2023 |
|
| Cost of revenues | $ | 314 |
$ | 230 |
|
| General and administrative | 2,282 |
2,509 |
|||
| Sales and marketing | 258 |
199 |
|||
| Technology and development | 879 |
466 |
|||
| Total stock-based compensation expense | $ | 3,733 |
$ | 3,404 |
|
The following table reconciles Net Income to Adjusted Net Income which is used to calculate Adjusted Diluted EPS:
| Three Months Ended December 31, | |||||||||||||
| (unaudited) | 2024 |
|
2023 |
||||||||||
| In thousands | Per share | In thousands | Per share | ||||||||||
| Net income and fully diluted EPS | $ | 172 |
|
— |
|
$ | 900 |
|
0.01 |
|
|||
| Adjustments1: | |||||||||||||
| Stock-based compensation expense | 3,733 |
|
0.03 |
|
3,404 |
|
0.03 |
|
|||||
| Tax payment on stock-based compensation | 91 |
|
0.00 |
|
60 |
|
0.00 |
|
|||||
| Effects of foreign currency | (445 |
) |
(0.00 |
) |
308 |
|
0.00 |
|
|||||
| Other non-recurring items2,3 | 3,712 |
|
0.03 |
|
678 |
|
0.01 |
|
|||||
| Tax adjustment4 | (3,333 |
) |
(0.03 |
) |
(863 |
) |
(0.01 |
) |
|||||
| Sub-total adjustments | 3,758 |
|
0.03 |
|
3,587 |
|
0.03 |
|
|||||
| Adjusted net income and adjusted diluted EPS | $ | 3,930 |
|
0.03 |
|
$ | 4,487 |
|
0.04 |
|
|||
| 1 Per share amounts are based on a weighted average number of shares outstanding on a fully-diluted basis. 2 For the three months ended December 31, 2024, includes corporate restructuring and professional fees incurred in conjunction with the pending Clearwater merger. 3 For the three months ended December 31, 2023, primarily includes the write-off of capitalized software and licenses related to a project which was abandoned in the fourth quarter of 2023 after management's decision to pursue an alternative path. 4 Income tax (benefit) calculated using effective tax rate for the period: |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250224817156/en/
Investors
Bill Wright
investors@enfusion.com
Media
Mollie Applegate
media@enfusion.com
Source: Enfusion, Inc.
FAQ
What was Enfusion's revenue growth in Q4 2024?
How many new clients did Enfusion acquire in Q4 2024?
What is Enfusion's Annual Recurring Revenue (ARR) for 2024?
When is the Clearwater Analytics acquisition of ENFN expected to close?
How did Enfusion's Net Dollar Retention Rate change in 2024?
